Abstract
Statement of translational relevance
Neoadjuvant or perioperative cisplatin and 5-fluorouracil based chemotherapy plus surgery is one standard of care for patients with resectable gastroesophageal cancer. However, chemotherapy benefits only a small proportion of patients, and validated biomarkers predictive of response or toxicity have been elusive.
We analysed the effect of multiple germline polymorphisms putatively associated with response or toxicity to chemotherapy in patients treated with chemotherapy plus surgery or surgery alone in the UK Medical
Research Council MAGIC Trial. One polymorphism in thymidylate synthase (TS), a 2R/2R tandem repeat, was significantly associated with overall survival in patients treated with chemotherapy, but not in patients treated with surgery alone. These findings suggest that neoadjuvant chemotherapy for patients with operable gastroesophageal cancer could be personalized based on germline polymorphism status.
Statement of significance:
We demonstrate in a randomised trial with a chemotherapy control arm that the presence of the thymidylate synthase 2R/2R genotype is associated with significantly improved overall survival for patients with operable gastroesophageal cancer treated with fluoropyrimidine based chemotherapy plus surgery. Further validation of this potential predictive biomarker for chemotherapy efficacy may be appropriate.
INTRODUCTION
Gastric and oesophageal cancers are the third and sixth most common causes of cancer death annually worldwide.(1) Neoadjuvant or perioperative chemotherapy is one standard treatment for patients with operable gastric or gastroesophageal adenocarcinoma prior to surgical resection. (2) (3) (4) (5) This approach is associated with a modest (6-13%) absolute overall survival advantage in terms of overall survival compared to surgery alone but also with chemotherapy related toxicities such as nausea and vomiting, and neutropenia.
Furthermore, following multimodality therapy half of resected patients develop incurable, metastatic cancer and therefore do not benefit from neoadjuvant chemotherapy. (2, 4) Better selection of patients for preoperative chemotherapy might avoid needless toxicity, however currently gastroesophageal cancer patients who are treated with neoadjuvant chemotherapy are selected for treatment based on radiological staging alone as there are no currently validated predictive biomarkers for chemotherapy.
Germline polymorphisms in genes associated with chemotherapy and drug metabolism have been validated as predictors of survival and toxicity outcomes across several tumour types including colorectal and breast cancer. (6) (7) (8) Although similar studies have examined the effects of polymorphisms in germline genes relating to chemotherapy metabolism in gastroesophageal cancer, most of these have been retrospective, and all lack an untreated control group. (9) (10) (11) 
Methods
Hematoxylin and eosin (H&E) stained tissue sections from resection specimens were reviewed by a histopathologist (AW). DNA was extracted from non-malignant tissue. Five sections (10 mm thick) were cut and deparaffinised using a standard protocol, and the area of interest was dissected using a sterile scalpel blade. Genomic DNA was extracted using Slides from all cases were reviewed and pathological response in tumour graded using the Mandard tumour regression grading (TRG) system.(12)
Genotype Analysis
Ten polymorphisms were selected based on a review of the literature and expected interaction with epirubicin, cisplatin and 5 fluorouracil chemotherapy. These are listed in This is based on based on a pathological response rate of 15% in the 3R group, which accounts for 70% of patients, and 30% in the 2R/2R group (which contains 30% of patients).
Due to the trial design and retrospective nature of these analyses, all results can only be seem as hypothesis generating and suggestive of future work, with significance levels set to limit the possibility of a type II error.
All analyses were conducted using Stata version 14. The MAGIC protocol was approved by the relevant ethics committees, and patients gave written informed consent for participation in the trial. The translational MAGIC protocol (TransMAGIC) received separate national ethics approval (11/LO/0566).
Results
Polymorphism data was available for 289/456 (63.4%) patients who underwent surgery in the MAGIC trial. There was no difference in distribution of sex, performance status, site of tumour, age or treatment arm between patients with and without polymorphism data, however patients without polymorphism data were more likely to undergo a palliative resection in the view of the operating surgeon (Supplementary Table 1 ). This resulted in a borderline difference in survival between patients who had polymorphism data available and those who did not, which was more pronounced in the surgery only arm (Supplementary Figure 1) .
Discordance in size based polymorphism assessment
We found that on duplicate runs that size based polymorphism assessment that discordance occurred at a rate of 32.7% and 4.2% for GSTT1 and TYMS (TS) respectively.(13) Due to the high rate of discordance in GSTT1 results for this polymorphism was not analysed further.
Genotype frequency
The frequency of each polymorphism genotype is described in Table 2 . Genotype frequency was consistent with previously published data and all were in Hardy-Weinberg equilibrium with the exception of DPYD rs1801159.
Genotype and pathological response to chemotherapy
The association between each polymorphism and pathological response to chemotherapy in chemotherapy treated patients is described in Table 3 . No polymorphism was statistically significantly associated with pathological response to chemotherapy.
Genotype and overall survival
Median overall survival for patients treated with surgery alone who had TS 2R/2R genotype was 1.76 years, compared to 1.68 years for 2R/3R and 2.09 years for 3R/3R (Table 4 , Figure 1 ). These differences were not statistically significant. In contrast, median overall survival for patients with a TS 2R/2R genotype treated with chemotherapy was not reached, whereas survival for 2R/3R and 3R/3R were 1.44 and 1.60 years respectively (log rank p value 0.0053). When all 3R genotypes were combined median overall survival was 1.44 years for chemotherapy treated patients vs not reached for 2R/2R genotype (HR 2.4, p=0.003).
The effect of TS genotype on overall survival in chemotherapy treated patients remained statistically significant when adjusted for the potential confounders of age, subtype, gender, site of primary, WHO, nodal status) ( Table 4 
Genotype and chemotherapy related toxicity
The presence of grade 3 or greater toxicity and association with polymorphism status are detailed in Supplementary Table 1 . DPYD2A IVS14+1G>A GA variant was associated with a non-statistically significant trend towards increased rates of ≥ Grade 3 diarrhoea The mean number of cycles of chemotherapy received for most polymorphisms was five (Supplementary Table 3) , with the exception of ERCC1 rs3212986 (GT+TT) variant who had a mean of four cycles (Kruskal-Wallis equality-of-populations rank test p= 0.0425).
Discussion
Our study is the first to evaluate the association between germline polymorphisms and pathological response, overall survival, and chemotherapy related toxicity for patients with operable gastroesophageal cancer in a randomised trial with a control group. We found that patients who have a 2R/2R thymidylate synthase genotype who were treated with perioperative ECF chemotherapy had statistically superior overall survival compared to those who had a 2R/3R or 3R/3R genotype. This difference was not apparent in patients who were treated with surgery alone, and a significant interaction between TS genotype status and treatment arm was noted Additionally, in our study, patients with a TS 2R2R genotype had a non-statistically significant higher rate of good pathological response (TRG to correct for multiplicity, and were confirmed with repeated simulation testing to account for any discrepancy in TS genotype assessment we do not think that this is likely to have unduly affected these results.
Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme in 5-fluorouracil catabolism and variation in DPD levels and activity have profound effects of fluoropyrimidine metabolism and toxicity. The most well described of these is a DPYD 2* splice variant polymorphism which results in a non-functional enzyme and is associated with fluoropyrimidine related toxicity in many studies. (6, (20) (21) (22) Although low patient deleterious allele frequency and lack of statistical significance due to correction for multiplicity means that we cannot be definitive in our conclusions, our results are consistent with these data.
However, we think that these results are of secondary importance to the survival outcomes presented.
We asked two questions from our dataset, firstly, can genotyping be used to differentiate between those who derive a survival benefit from perioperative chemotherapy and those who do not, and secondly, if these genotypes were assessed preoperatively, would it In the MAGIC trial, the most common grade 3 or greater chemotherapy associated toxicity was neutropenia which is likely to be due to epirubicin and which is not predicted by any of the polymorphisms which we examined. Therefore, routine testing for DPYD 2A* polymorphisms is unlikely to significantly decrease toxicity in patients treated with MAGIC type chemotherapy.
The interaction between chemotherapy and genotype is complex, and coloured by many other clinical variables such as age, ethnicity, gender, hepatorenal function, and the interaction between individual components of each chemotherapy regimen. This has profound implications for the accuracy of toxicity or outcome prediction using genotyping.
One potential flaw relating specifically to this work is that not all MAGIC trial participants were included in the current study as not all provided tissue for analysis, therefore we caution that the analysis could be underpowered to detect small effect sizes. 
